IGM Biosciences Inc expected to post a loss of $1.25 a share - Earnings Preview

IGM Biosciences

28/03/2023 21:15

* IGM Biosciences Inc  IGMS.OQ   IGMS.O  is expected to show
a
rise in quarterly revenue when it reports  results on March 30. 
    * The Mountain View California-based  company is expected to
report revenue of $301.25 thousand, according to the mean
estimate from 8 analysts, based on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for IGM Biosciences Inc
is
for a loss of $1.25 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for IGM
Biosciences
Inc is $37​, above​ its last closing price of $16.41. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -1.44       -1.43      -1.32     Beat    7.5
 Jun. 30 2022  -1.27       -0.94      -1.33     Missed  -41.5
 Mar. 31 2022  -1.61       -1.61      -1.53     Beat    5.2​
 Dec. 31 2021  -1.37       -1.54      -1.50     Beat    2.7
 ​​Sep.        -1.37       -1.37      -1.32     Beat    3.4
 30 2021                                                
 Jun. 30 2021  -1.19       -1.17      -1.16     Beat    0.6​
 Mar. 31 2021  -0.96       -0.98      -0.95     Beat    3.1
 Dec. 31 2020  -0.71       -0.87      -0.79     Beat    9
 This summary was machine generated March 28 at 20:15 GMT.  All
figures in US dollars  unless otherwise stated